Notice2022-00522
National Institute on Drug Abuse; Notice of Closed Meeting
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
January 13, 2022
Issuing agencies
Health and Human Services DepartmentNational Institutes of Health
Full Text
<html>
<head>
<title>Federal Register, Volume 87 Issue 9 (Thursday, January 13, 2022)</title>
</head>
<body><pre>
[Federal Register Volume 87, Number 9 (Thursday, January 13, 2022)]
[Notices]
[Page 2170]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2022-00522]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended, notice is hereby given of the following meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and/or contract proposals
and the discussions could disclose confidential trade secrets or
commercial property such as patentable material, and personal
information concerning individuals associated with the grant
applications and/or contract proposals, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel; Synthesis and Distribution of Opioid and Related
Peptides.
Date: January 26, 2022.
Time: 1:00 p.m. to 2:00 p.m.
Agenda: To review and evaluate contract proposals.
Place: National Institutes of Health, National Institute on Drug
Abuse, 301 North Stonestreet Avenue, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Sheila Pirooznia, Ph.D., Scientific Review
Officer, Scientific Review Branch, Division of Extramural Review,
National Institute on Drug Abuse, NIH, 301 North Stonestreet Avenue,
MSC 6021, Bethesda, MD 20892, (301) 496-9350,
<a href="/cdn-cgi/l/email-protection#d5a6bdb0bcb9b4fba5bca7babaafbbbcb495bbbcbdfbb2baa3"><span class="__cf_email__" data-cfemail="33405b565a5f521d435a415c5c495d5a52735d5a5b1d545c45">[email protected]</span></a>.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug
Abuse Scientist Development Award for Clinicians, Scientist
Development Awards, and Research Scientist Awards; 93.278, Drug
Abuse National Research Service Awards for Research Training;
93.279, Drug Abuse and Addiction Research Programs, National
Institutes of Health, HHS)
Dated: January 7, 2022.
Tyeshia M. Roberson-Curtis,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2022-00522 Filed 1-12-22; 8:45 am]
BILLING CODE 4140-01-P
</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>Indexed from Federal Register on January 13, 2022.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.